The healthcare industry in the U.S. has spent a whole generation talking about moving from a fee-for-service to a value-based model, focusing more on improved patient outcomes and early interventions rather than disease treatment. This shift has occurred gradually, sometimes purposefully, and sometimes in fits and starts, but overall, it has been slower than expected. Nowhere is this more apparent than in the chronic kidney disease (CKD) patient population. What makes now different?
Since March 2020, the coronavirus pandemic has laid bare fissures in healthcare’s firmament, especially related to its most vulnerable populations. The silver lining is that the crisis has also sped the confluence of multiple factors – such as improved technology, changing federal regulations and increased care coordination – that are helping us smooth the cracks, making this the perfect time to accomplish some of the positive changes we’ve been working toward for decades.